Issue 22, 28 June 2021
The newsletter on COVID-19 vaccination is an RIVM publication with up-to-date information for professionals involved in COVID-19 vaccination.
Progress report on the COVID-19 vaccination campaign
The 15 millionth COVID-19 vaccination was administered last week.
Study on heterologous vaccination schedules
Until now, it has been common practice to administer the same COVID-19 vaccine in two doses (homologous vaccination schedules). Multiple studies on heterologous vaccination schedules are being conducted and more and more data on immunogenicity and reactogenicity is being published. A recent German study on a vaccine regimen involving initial AstraZeneca vaccination followed by an mRNA vaccination showed that the series induced strong humoral and cellular response was found with acceptable reactogenicity profile. A Health Council advisory report on COVID-19 vaccination involving heterologous vaccination schedules is expected soon.
Updated implementation guidelines for COVID-19 vaccination
The implementation guidelines for COVID-19 vaccination 2021 have been updated. The latest version of the implementation guidelines is always available online (in Dutch). Section 1.3 outlines all major changes compared to the previous version; more minor interim changes are listed under Version Management (at the end of the document).
Do you have questions about the Digital COVID Certificate (DCC)? Click here. The most frequently asked questions about the CoronaCheck app can be found here here. For other questions about the CoronaCheck app, please call 0800-1421 (free) or email email@example.com.
This video offers a peek at COVID-19 vaccination in the Caribbean part of the Kingdom of the Netherlands.
Editors: Vaccination implementation, National Coordination Centre for Communicable Diseases Control (LCI).
For questions and/or comments about this newsletter, healthcare professionals can send a message to firstname.lastname@example.org.
Private citizens can call the public information number 0800 - 1351 with their questions.